MMJ International Holdings Joins Federal Lawsuit on 4/20 to Stop CMS From Introducing Unvalidated Cannabinoid Products Into America's 65+ Population
"MMJ International Holdings Joins Smart Approaches to Marijuana et al, Federal Challenge to CMS Hemp Program on 4/20: "Botanical Therapies Must Meet FDA Standards-Not Political Timelines" said Duane Boise MMJ International Holdings CEO.
WASHINGTON, April 20, 2026 (Newswire.com) - On a day traditionally associated with cannabis advocacy, MMJ International Holdings announced its support for litigation aligned with Smart Approaches to Marijuana et al challenging the Centers for Medicare & Medicaid Services' cannabinoid reimbursement framework, warning that federal healthcare dollars should not be used to introduce unvalidated botanical products into the Medicare population.
The company's position is clear:
Botanical therapies must meet reproducibility, safety, and clinical-trial standards before federal adoption.
MMJ International Holdings is supporting the legal effort alongside nationally recognized pain specialist Kenneth Finn, M.D., and constitutional attorney Ilya Shapiro of Burke Law Group, who are raising concerns about the scientific and regulatory implications of introducing hemp derived cannabinoid products into Medicare access pathways without FDA validation.
This Is Not Anti-Cannabis. It Is Pro-Science.
MMJ emphasized that its position is frequently misunderstood by fake news outlets.
This is not opposition to cannabis medicine.
It is opposition to bypassing the regulatory framework that protects patients.
"April 20 has always been a day about access," said Duane Boise, President & CEO of MMJ International Holdings.
"Now it must become a day about standards. Botanical medicines hold enormous promise-but promise alone is not enough. Patients deserve therapies that are reproducible, tested, and safe."
The Hemp Industry Did Not Collapse Because of Regulators
According to MMJ leadership, the tightening regulatory environment facing hemp-derived THC products was predictable-and avoidable.
Across multiple states and now federally, policymakers are responding to:
escalating THC concentrations in "hemp" consumer products
lack of reproducible formulations
absence of stability-controlled dosage forms
inconsistent labeling accuracy
absence of controlled clinical trials demonstrating efficacy
These same structural weaknesses are now emerging in parts of the broader marijuana marketplace.
High-potency products without pharmaceutical reproducibility are drawing the same scrutiny that triggered the federal November 12 intoxicating hemp restrictions now approaching implementation.
The lesson is straightforward:
Markets built on loopholes rarely survive contact with federal healthcare policy.
CMS Should Not Introduce Unvalidated Cannabinoids Into the Medicare Population
MMJ's strongest concern centers on the proposed role of Centers for Medicare & Medicaid Services in supporting access to hemp-derived cannabinoid products before FDA approval pathways are completed.
Medicare beneficiaries represent the most medically vulnerable population in the United States.
Introducing non-IND botanical products into that population without:
reproducibility standards
stability validation
pharmacokinetic characterization
controlled efficacy trials
creates what MMJ describes as a dangerous policy precedent.
"Federal healthcare programs should never become distribution channels for products that have not met the same safety and efficacy requirements as every other medicine," Boise said.
FDA Botanical Drug Guidance Already Defines the Correct Path
The United States does not prohibit plant-based medicines.
It regulates them.
The FDA Botanical Drug Development Guidance requires:
controlled chemistry
batch-to-batch consistency
contaminant testing
validated dosing
stability verification
clinical-trial evidence
Those expectations apply equally to:
cannabinoids
psychedelics
plant-derived neurological therapies
and any future botanical medicines entering federal healthcare systems
MMJ followed that pathway deliberately.
MMJ Chose the Pharmaceutical Route When Others Chose Retail Markets
While much of the cannabinoid sector pursued state-level commercialization strategies, MMJ International Holdings invested in a federal scientific pathway that included:
FDA Investigational New Drug submission
standardized cannabinoid soft-gel dosage development
orphan-drug designation for Huntington's disease
DEA analytical laboratory registration
DEA bulk-manufacturing application for clinical supply
This approach reflects a long-term commitment to medical legitimacy rather than short-term market positioning.
A Warning to the Marijuana Industry on 4/20
According to MMJ leadership, the marijuana industry now faces the same crossroads the hemp industry encountered several years ago.
Without:
reproducibility
stability-validated dosage forms
controlled clinical trials
and federal compliance alignment
parts of the sector risk repeating the same regulatory cycle now reshaping hemp.
This is not speculation.
It is already happening.
Why the Lawsuit Matters
By supporting SAM's litigation challenging CMS's cannabinoid-access framework, MMJ International Holdings is reinforcing a simple national principle:
Federal reimbursement should follow science-not precede it.
The company's position is shared by clinicians, regulatory scholars, and constitutional policy experts participating in the legal challenge.
Together, they are asking a straightforward question:
Should taxpayer-funded healthcare programs introduce botanical therapies before those therapies meet FDA drug-development standards?
MMJ International Holdings believes the answer must remain no.
And on this 4/20, the company is reaffirming its commitment to ensuring that the future of cannabinoid medicine is defined not by loopholes-but by evidence.
Madison Hisey
[email protected]
203-231-8583
SOURCE: MMJ International Holdings
Source: MMJ International Holdings
Share:
Tags: botanical extract consistency FDA requirements cannabis medicine, botanical therapies reproducibility safety clinical trial standa, cannabinoid clinical validation requirements before reimbursemen, cannabinoid medicine FDA approval pathway United States, cannabinoid pharmaceutical softgel clinical trials United States, cannabinoid pharmacokinetics dosing reproducibility regulatory c, cannabinoid reimbursement policy constitutional challenge United, cannabinoid safety standards federal healthcare adoption require, cannabinoid therapy neurological disease FDA clinical trials pip, cannabis chemistry manufacturing controls CMC botanical drugs FD, cannabis IND clinical trials Huntington’s disease MMJ BioPharma, cannabis investor regulatory outlook Schedule III healthcare ado, cannabis medical legitimacy FDA pathway MMJ International Holdin, cannabis medicine seniors Medicare safety concerns cannabinoids, cannabis policy Washington DC regulatory update April 2026, cannabis product stability pharmaceutical standards FDA pathway, cannabis regulatory alignment FDA DEA CMS conflict United States, cannabis Schedule III rescheduling implications healthcare reimb, CMS beneficiary engagement incentive cannabinoid policy risk, CMS cannabinoid access framework lawsuit analysis United States , CMS cannabinoid reimbursement controversy seniors, CMS hemp derived cannabinoid access policy litigation, CMS vs FDA cannabinoid regulatory conflict analysis, DEA cannabis bulk manufacturing registration MMJ BioPharma Culti, Duane Boise, Duane Boise DEA, Duane Boise FDA, Duane Boise Florida, FDA botanical drug development guidance cannabinoids policy, federal botanical medicine approval standards United States heal, federal cannabis reimbursement before FDA approval controversy, federal cannabis science first reimbursement second policy debat, federal healthcare cannabinoid reimbursement debate United State, hemp industry regulatory collapse intoxicating cannabinoids poli, hemp THC Medicare population safety concerns, hemp THC regulatory crackdown United States 2026, Huntington’s disease cannabinoid therapy clinical development Un, Ilya Shapiro Burke Law Group CMS lawsuit cannabinoids, intoxicating hemp restrictions November 12 federal law cannabino, Kenneth Finn MD cannabis policy Medicare safety concerns, marijuana industry reproducibility stability clinical trial conc, Medicare CBD pilot program lawsuit challenge, Medicare exposure unapproved cannabinoid therapies policy risk, MMJ International Holdings lawsuit CMS cannabinoid policy, MMJ joins SAM lawsuit cannabis reimbursement Medicare, multiple sclerosis cannabinoid therapy research FDA pathway, orphan drug designation Huntington’s disease cannabinoids FDA, pharmaceutical cannabinoids vs dispensary cannabis policy differ, plant based medicine regulatory standards United States FDA bota, seniors exposed to hemp THC policy concerns Medicare cannabinoid, Smart Approaches to Marijuana CMS lawsuit 2026, Washington DC cannabis policy leadership cannabinoid medicine st
